Search Results - Endovascular Today

evt | Article | September 2005

An Interview With Gary Ansel, MD

A top interventional cardiologist shares his insight on the future of SFA treatment and what to expect from VIVA 2005.

By Gary Ansel, MD

evt | News | December 4, 2009

Stroke Prevention in Carotid Artery Stenting

What are the primary goals of neuroprotection during carotid artery stenting (CAS)?The primary goals of neuroprotection during CAS are to prevent debris from embolizing to the distal vascular bed and causing a stroke while acting as a stable platform from which to deliver the balloon and stent.

evt | Article | September 2021

BioMimics 3D: Impacting Outcomes Through Stent Design

Gary Ansel, MD; John H. Rundback, MD; and Thomas Zeller, MD, share their experience with the femoropopliteal stent with the innovative 3D helical centerline.

evt | Article | September 2021

United States Regulatory Perspectives on Paclitaxel in PAD

Moderator Dr. Gary Ansel asks representatives from the FDA’s Center for Devices and Radiological Health about controlling for ascertainment and investigator bias in future vascular device trials, potential changes for drug-based device approvals, how the agency weighs the level of data required for approval of new vascular devices, the statistical strength of the data from general use studies, and the level of data needed to update FDA’s position on paclitaxel-containing devices.

With Eleni Whatley, PhD; Misti Malone, PhD; Sara Royce, PhD; and Kenneth Cavanaugh, PhD

evt | Article | December 2022 Supplement

Have We Found the Holy Grail for Thromboembolectomy?

A conversation with Dr. Gary Ansel, inventor of the Pounce™ Thrombectomy System.

evt | Article | December 2025 Supplement

Pounce™ Thrombectomy Platform: Physician-Designed for Simplicity and Effectiveness

By Gary Ansel, MD, and Chad Stark

evt | Article | May 2025

Pounce™ Thrombectomy Platform: Physician-designed for simplicity and effectiveness

By Gary Ansel, MD, and Chad Stark

evt | Article | January 2013

Perspectives on Access and Closure

A multispecialty panel's insights into current challenges and recent developments.

With Gary Ansel, MD; Frank Arko, MD; J.A. Mustapha, MD; Peter Schneider, MD; and Jos C. van den Berg, MD, PhD

evt | Article | United States November 2014 Supplement

Drug Elution, Data, and Decisions

What the data tell us about how to integrate drug-eluting technology into our daily practice.

By Gary Ansel, MD, and John A. Phillips, MD

evt | Article | October 2014

When would you elect to use a DCB versus a DES for SFA interventions, and what guides your decision making?

With Francesco Liistro, MD; Sebastian Sixt, MD; Gary Ansel, MD; and Marianne Brodmann, MD

evt | Article | November 2024 Supplement

Embracing a New Era: Putting Data Into Practice

Dr. Silver moderates a panel of experts who discuss their experiences with the Neuroguard IEP® System, insights into the data, device design characteristics, and impact on the field.

By Mitchell J. Silver, DO, FACC, FSVM, RPVI; Gary Ansel, MD; William A. Gray, MD, MSCAI, FACC; Elad I. Levy, MD, MBA; Sean P. Lyden, MD; S. Jay Mathews, MD, FACC, FSCAI; Robert Mendes, MD, FACS; D. Christopher Metzger, MD, FACC; Kenneth Rosenfield, MD, MHCDS; Adnan H. Siddiqui, MD, PhD; and Peter A. Soukas, MD

evt | News | October 17, 2011

VIVA 2011: 3-Year VIBRANT Results for Bare Stents and Stent Grafts in Long SFA Disease

October 18, 2011—Gary Ansel, MD, presented 3-year results from VIBRANT during a late-breaking clinical trial session at the VIVA 2011: Vascular Interventional Advances meeting in Las Vegas, Nevada.

evt | News | September 13, 2017

Data From Early Feasibility PREVEIL Study Presented for Surmodics SurVeil DCB

September 13, 2017—Surmodics, Inc. announced that data from the PREVEIL early feasibility study of the company’s SurVeil drug-coated balloon (DCB) were reported by Gary Ansel, MD, in a late-breaking clinical trial presentation at the VIVA 17, Vascular Interventional Advances, conference held September 11–14 in Las Vegas, Nevada.

evt | News | April 27, 2022

Surmodics’ Pounce Thrombectomy System Shows 100% Technical Success in FIH Data Procedures

April 27, 2022—Surmodics, Inc. announced that data from the 20 first-in-human (FIH) procedures using the company’s FDA-cleared Pounce thrombectomy system to treat peripheral artery disease (PAD) were presented by Gary Ansel, MD, the inventor of the Pounce device, at the Charing Cross International Symposium 2022 held April 26-28 in London, United Kingdom.

evt | News | June 14, 2018

FDA Approves Extended Balloon Lengths for Medtronic's In.Pact Admiral DCB

June 15, 2018—Medtronic announced that it has received US Food and Drug Administration (FDA) approval for 200- and 250-mm lengths of its In.Pact Admiral drug-coated balloon to treat long superficial femoral artery (SFA) lesions in patients with peripheral artery disease (PAD).

evt | News | December 17, 2012

Cook Launches Zilver PTX Peripheral Drug-Eluting Stent in the United States

December 18, 2012—Cook Medical (Bloomington, IN) announced the first commercial use of the Zilver PTX paclitaxel-eluting stent in the United States.

evt | News | April 24, 2017

Medtronic's In.Pact Admiral Drug-Coated Balloon Studied in Complex PAD Patients

April 25, 2017—Medtronic announced the presentation of results for its In.Pact Admiral drug-coated balloon (DCB) from two new subanalyses from the IN.PACT Global Study in patients with peripheral artery disease (PAD). The new data were reported at the annual 2017 Charing Cross Symposium in London, United Kingdom.

evt | News | May 27, 2020

VIVA's Paclitaxel Analysis Finds Increased Mortality Risk, But No Dose Association; Lead Author Encourages Close Read

May 27, 2020—Earlier this month, VIVA Physicians announced the publication of an analysis of mortality and paclitaxel-coated devices by Krishna Rocha-Singh, MD, et al, which is available online ahead of print in Circulation.

evt | Article | September 2019

Ask the Experts: How Do You Define ‘High Risk for Restenosis'?

With Gary M. Ansel, MD; Herbert D. Aronow, MD, MPH, FACC, FSCAI, FSVM; Marianne Brodmann, MD; Koen Deloose, MD; Andrew Holden, MBChB, FRANZCR, EBIR; John H. Rundback, MD; and Peter A. Schneider, MD

evt | News | March 14, 2024

Healthcare Inroads Announces Global Launch

March 14, 2024—Healthcare Inroads, LLC, (HCIR) announced its launch as a partnership of clinicians and allied specialists dedicated to accelerating the goals and milestones of medical device companies, investors, and health care systems in the United States, Europe, and Asia.